cardiovascular medicine
Conditions
Interventions
Control Intervention:Quadruple Live Bifidobacterium Intervention
Sponsors
Guidong People’s Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients meeting the diagnostic criteria for heart failure with preserved ejection fraction (HFpEF) according to the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the Chinese Expert Consensus on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction (2025 Edition); aged 18 years or older, regardless of sex; New York Heart Association (NYHA) functional class I–III; clinically stable heart failure symptoms on the basis of standard therapy and able to comply with the study protocol; voluntarily providing written informed consent and able to participate in and complete the study.
Exclusion criteria
Exclusion criteria: Participants will be excluded if they have used or are currently using probiotic preparations within 7 days before enrollment; have serious comorbidities, including malignant tumors, hyperthyroidism, severe chronic obstructive pulmonary disease, severe infections requiring antibiotic treatment, electrolyte disturbances, poorly controlled blood glucose, or motor dysfunction; are pregnant or breastfeeding women; have severe hepatic or renal dysfunction; are receiving and unable to discontinue medications that may affect the action of probiotics, such as antibiotics; have cardiogenic shock, severe arrhythmias, recent cardiac resynchronization therapy, heart transplantation, or mechanical circulatory support; have heart failure secondary to structural heart disease, congenital heart disease, myocarditis, cardiac tumors, or recent acute myocardial infarction; have known allergy to any component of the probiotic preparation; have intestinal diseases that may interfere with the gut microbiota, including intestinal infection, inflammatory bowel disease, intestinal obstruction, or colon cancer; are unable to undergo echocardiographic examination; are unable or unwilling to comply with the study-required diet and lifestyle regimen; are immunocompromised or receiving immunosuppressive therapy; or have any other condition that, in the opinion of the investigators, makes them unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac Function Parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory factors;Health-Related Quality of Life; | — |
Countries
China
Contacts
Public ContactCen Kaiyuan
Guidong People’s Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed